The Impact of Age on the Response of Patients With Superficial Bladder Cancer to Intravesical Immunotherapy

Journal of Urology

Volumn 175, Issue 5, 2006, Pages 1634-1640

  Joudi, Fadi N ^a   Smith, Brian J ^b   O'Donnell, Michael A ^a   Konety, Badrinath R ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b Department of Biostatistics ^*  (United States)

Author keywords

aging; bladder; bladder neoplasms; interferons; Mycobacterium bovis

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; RECOMBINANT ALPHA2B INTERFERON; TICE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; SUPERFICIAL CANCER; TOXICITY; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MALE; MIDDLE AGED; URINARY BLADDER NEOPLASMS;

EID: 33645971937     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00973-0     Document Type: Article

References (21)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10
2. Malkowicz S.B. Management of superficial bladder cancer. In: Walsh P.C., Retik A.B., Vaughan Jr. E.D., and Wein A.J. (Eds). Campbell's Urology. 8th ed. vol. 4 (2002), W. B. Saunders Co, Philadelphia 2785-2802 sect. X, chapt. 77
3. Lynch C.F., and Cohen M.B. Urinary system. Cancer, suppl 75 (1995) 316
4. Punnen S.P., Chin J.L., and Jewett M.A. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer. results with intravesical BCG and Interferon combination therapy. Can J Urol 10 (2003) 1790
5. Lam J.S., Benson M.C., O'Donnell M.A., Sawczuk A., Gavazzi A., Wechsler M.H., et al. Bacillus Calmete-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21 (2003) 354
6. O'Donnell M.A., Lilli K., and Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172 (2004) 888
7. Population Projections Program, Population Division, United States Census Bureau, Washington, D. C. Available at http://www.census.gov/population/projections. Accessed July 2005.
8. Goodwin J.S., Samet J.M., Key C.R., Humble C., Kutvirt D., and Hunt C. Stage at diagnosis of cancer varies with the age of the patient. J Am Geriatr Soc 34 (1986) 20
9. Lawson D.H. Update on the systemic treatment of malignant melanoma. Semin Oncol, suppl 31 (2004) 33
10. Figlin R.A., Abi-Aad A.S., Belldegrun A., and deKernion J.B. The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma. Semin Oncol, suppl 18 (1991) 102
11. Ratliff T.L., Ritchey J.K., Yuan J.J., Andriole G.L., and Catalona W.J. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150 (1993) 1018
12. Mulders P.F., Meyden A.P., Doesburg W.H., Oosterhof G.O., Debruyne F.M., and The Dutch South-Eastern Urological Collaborative Group. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. Br J Urol 73 (1994) 403
13. Takashi M., Wakai K., Hattori T., Furuhashi K., Ono Y., Ohshima S., et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy. significance of concomitant carcinoma in situ. Int Urol Nephrol 33 (2002) 41
14. Gillis S., Kozak R., Durante M., and Weksler M.E. Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans. J Clin Invest 67 (1981) 937
15. Thoman M.L., and Weigle W.O. Lymphokines and aging. interleukin-2 production and activity in aged animals. J Immunol 127 (1981) 2102
16. Gillis S. Interleukin 2. biology and biochemistry. J Clin Immunol 3 (1983) 1
17. Saint F., Kurth N., Maille P., Vordos D., Hoznek A., Soyeux P., et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 107 (2003) 434
18. Zhang H.G., and Grizzle W.E. Aging, immunity, and tumor susceptibility. Immunol Allergy Clin North Am 23 (2003) 83
19. Denduluri N., and Ershler W.B. Aging biology and cancer. Semin Oncol 31 (2004) 137
20. de Reijke T.M., de Boer E.C., Kurth K.H., and Schamhart D.H.J. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. processing, stability and prognostic value. J Urol 155 (1996) 477
21. Chen W.F., Liu S.L., Gao X.M., and Pang X.W. The capacity of lymphokine production by peripheral blood lymphocytes from aged humans. Immun Invest 15 (1986) 575